Targeted transposition for use in epigenetic studies

Abstract

Disclosed herein are compositions, methods and kits useful for epigenetic analysis based on the use of transposons that are targeted to specific regions of chromatin based on DNA-DNA interactions, protein-protein interactions, RNA-RNA interactions, and nucleic acid-protein interactions.

Description

FIELD OF THE INVENTION[0001]The present invention is in the field of epigenetics. More specifically, compositions, methods and kits useful for epigenetic analysis based on the use of transposons to specifically target specific regions of chromatin.BACKGROUND OF THE DISCLOSUREOverview of Epigenetic Mechanisms[0002]Epigenetics is broadly defined as changes in phenotype that are heritable but do not involve changes in the DNA sequence, and, from a historical perspective, stems from long-standing studies of seemingly anomalous (i.e., non-Mendelian) and disparate patterns of inheritance in many organisms [1]. Examples include variation of embryonic growth, mosaic skin coloring, random X inactivation, and plant paramutation. Discoveries in a large number of different model systems have been pivotal in identifying the three principle epigenetic mechanisms of (i) histone modifications, (ii) DNA methylation, and (iii) non-coding RNAs, which function in concert to influence cellular processes...

AI Technical Summary

Benefits of technology

The patent describes methods and reagents for making nucleic acid sequence libraries from eukaryotic and prokaryotic organisms. These methods involve extracting and optionally fragmenting chromatin from a prepared sample, adding a protein-oligonucleotide conjugate containing an extraction moiety, allowing the conjugate to locate at its target protein or DNA-binding site in the chromatin fragments, and tagging the nucleic acid in the fragments with the conjugate. The tagged nucleic acid can then be sequenced. The patent also describes antibody-transposome complexes and the use of these complexes for proximity ligation reactions. Additionally, the patent describes methods for enriching for DNA methylated genomic regions using transpososome-antibody / oligonucleotide complexes.

Problems solved by technology

In spite of all the advances to date, however, the epigenetics research field is still in the discovery phase, with many mechanistic questions remaining unanswered and many key players yet to be identified.

While these improvements have increased the magnitude of sequence information available for analysis from a single reaction, the limitations associated with efficient immunocapture of protein-associated DNA have not been addressed.

In addition, the sample size requirement remains a considerable barrier in some research areas, such as embryology and stem cells where cell numbers are very limiting, and is further compounded by the limitation that the only a single protein can be analyzed in each ChIP experiment.

The number of cells required is thus directly proportional to the number of proteins to be analyzed, impacting cost and time considerations.

An additional challenge stems from the need of ultra-high affinity antibodies for use in this technique.

In addition, ChIP analysis is limited by the small percentage of antibodies that work effectively in the method.

Images